Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (8)
Type
(
1 selected
)
Type
Guidance (282)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (15)
Medical technologies guidance (7)
Technology appraisal guidance (282)
Apply filters
Showing 226 to 250 of 282
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413
Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009
Technology appraisal guidance
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]
Technology appraisal guidance
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]
Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]
Technology appraisal guidance
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]
Technology appraisal guidance
Teprotumumab for treating thyroid eye disease ID 6432
Technology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918
Technology appraisal guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]
Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]
Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer TS ID 11951
Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation TS ID 11841
Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]
Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome TS ID 11794
Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID 5077]
Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer TS ID 10693
Technology appraisal guidance
Tocilizumab for treating systemic sclerosis (ID1396)
Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
Technology appraisal guidance
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845
Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]
Technology appraisal guidance
Previous page
1
…
8
9
Current page
10
11
12
Page
10
of
12
Next page
Results per page
10
25
50
All
Back to top